A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to Less Than 24 Months, With Sickle Cell Disease (HESTIA4)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

06 Nov 2019 Results of HESTIA4 study assessing whether ticagrelor exposure in children less than 24 months old is similar to that in older children and for further dose selection, final PK data from children 2 to <18 years were used from HESTIA1 study, released in 61st Annual Meeting and Exposition of the American Society of Hematology
07 Jun 2019 Status changed from recruiting to completed.
02 Jan 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com